— Know what they know.
Not Investment Advice
Also trades as: NVO (NYSE) · $vol 924M · NOVO-B.CO (CPH) · $vol 334M · NOV.DE (XETRA) · $vol 17M · NOVC.DE (XETRA) · $vol 5M

NONOF OTC

Novo Nordisk A/S
1W: -3.1% 1M: +14.8% 3M: -8.0% YTD: -16.1% 1Y: -32.2% 3Y: -45.6% 5Y: +20.4%
$44.25
-0.39 (-0.88%)
 
Weekly Expected Move ±5.1%
$40 $43 $45 $47 $50
OTC · Healthcare · Biotechnology · Alpha Radar Buy · Power 74 · $196.6B mcap · 3.17B float · 0.0062% daily turnover · Short 41% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$196.6B
52W Range34-82.5
Volume2,190
Avg Volume196,936
Beta0.35
Dividend$1.80
Analyst Ratings
18 Buy 4 Hold 3 Sell
Consensus Buy
Company Info
CEOMaziar Mike Doustdar
Employees77,406
SectorHealthcare
IndustryBiotechnology
IPO Date2010-05-07
Novo Allé 1
Bagsvaerd 2880
DK
45 44 44 88 88
About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms